ARS Pharmaceuticals, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from ARS Pharmaceuticals, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 89% of Healthcare companies in United States.
- Growth Efficiency Ratio: Sales grew 6,304% in 3 years, but profit fell: $165 less profit per $100 of extra sales. Lower than 89% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-201.1×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 89% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 1/3Sales grew in 1 of the last 3 years; profit grew in 1 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
−$165Sales grew 6,304% in 3 years, but profit fell: $165 less profit per $100 of extra sales.
Lower than 89% of Healthcare companies in United States.
Asset Productivity Ratio
+6304% / +16%In 3 years sales changed by +6304% while total assets changed by +16%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
+35%Cash, after subtracting all debt, equals 35% of its market value (net cash).
Higher than 71% of Healthcare companies in United States.
Tangible Assets Ratio
96%Of every $100 the company owns, $96 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 75% of Healthcare companies in United States.
Tangible Net Worth Ratio
87%Of every $100 of net worth, $87 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 69% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
ARS Pharmaceuticals, Inc. made a loss over the last year. ARS Pharmaceuticals, Inc. owes $0.95 for every $1 it owns. ARS Pharmaceuticals, Inc. made a loss in the year to Dec 2025, after a profit the year before.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossARS Pharmaceuticals, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
34.34The share price is 34.34 times ARS Pharmaceuticals, Inc.'s book value per share, higher than 97% of Healthcare companies in United States.
Market cap
$430 MThe total market value of all of ARS Pharmaceuticals, Inc.'s shares at today's price (share price × number of shares), larger than 53% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$13 MWhat ARS Pharmaceuticals, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.13Net worth divided by the number of shares. The share price of $4.32 is 34.3 times this, which is the P/B above.
Return on equity (ROE)
-210.3%ARS Pharmaceuticals, Inc. lost 210.3% of its shareholders' money over the last year, lower than 85% of Healthcare companies in United States.
Owes vs Owns
0.95×ARS Pharmaceuticals, Inc. owes $0.95 for every $1 it owns (high), higher than 85% of Healthcare companies in United States.
Dividend yield
NoneARS Pharmaceuticals, Inc. does not currently pay a dividend.
Revenue growth
-5%Revenue fell 5% in the year to Dec 2025, and grew 300% a year on average over 3 years.
Profit growth
LossARS Pharmaceuticals, Inc. made a loss in the year to Dec 2025, after a profit the year before.
Profit margin
-203.3%ARS Pharmaceuticals, Inc. lost $203 for every $100 of revenue.
Interest cover
Not coveredARS Pharmaceuticals, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashARS Pharmaceuticals, Inc. held $149 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For ARS Pharmaceuticals, Inc.: $430 M ÷ $13 M (30 Jun 2026) = 34.3.
What is ARS Pharmaceuticals, Inc.'s return on equity?
ARS Pharmaceuticals, Inc. lost 210.3% of its shareholders' money over the last year, lower than 85% of Healthcare companies in United States.
How much does ARS Pharmaceuticals, Inc. owe compared with what it owns?
ARS Pharmaceuticals, Inc. owes $0.95 for every $1 it owns (high), higher than 85% of Healthcare companies in United States.
Does ARS Pharmaceuticals, Inc. pay a dividend?
No. ARS Pharmaceuticals, Inc. does not currently pay a dividend.
Is ARS Pharmaceuticals, Inc.'s revenue growing?
Revenue fell 5% in the year to Dec 2025, and grew 300% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.